Shattuck Labs, INC Form 4 insider transactions

Shattuck Labs' Chief Financial Officer, Andrew R. Neill, reported the acquisition of 549,800 stock options and the disposition of 6,660 common shares for tax purposes.

Shattuck Labs, Inc. CEO Taylor Schreiber was granted 1,548,300 stock options with an exercise price of $4.75, vesting over four years.

OrbiMed Advisors and its affiliates significantly increased their beneficial ownership in Shattuck Labs, Inc. through a private placement of common stock and warrants.

Shattuck Labs completed a private placement, raising approximately $16 million through the sale of common stock and warrants to OrbiMed funds.

Shattuck Labs, Inc. director Mona Ashiya was granted 66,300 stock options with an exercise price of $0.99, vesting over three years starting August 28, 2025.

Shattuck Labs Director Daniel G. Baker was granted options to purchase 66,300 shares of common stock at an exercise price of $0.99.

Shattuck Labs' General Counsel, Stephen Stout, acquired 12,805 common shares and warrants in a private placement at $0.8677 per unit.

Shattuck Labs' Chief Financial Officer, Andrew R. Neill, acquired 64,027 shares of common stock and accompanying warrants in a private placement.

Shattuck Labs Director Clay B. Siegall acquired 128,054 shares of common stock and an equal number of warrants in a private placement.

Shattuck Labs' Chief Technical Officer, Abhinav A. Shukla, acquired 5,122 shares and warrants in a private placement, signaling insider confidence.

Shattuck Labs CEO Taylor Schreiber acquired 25,610 shares and warrants in a private placement, increasing his direct beneficial ownership.

Redmile Group, a 10% owner and director, acquired pre-funded and common warrants in Shattuck Labs as part of a private placement.

Shattuck Labs, Inc. Director Michael Lee was granted 33,150 stock options with an exercise price of $0.82, vesting on the earlier of one year from the grant date or prior to the next annual meeting.

Redmile Group, LLC and its principal Jeremy Green, both 10% owners and directors of Shattuck Labs, Inc., reported the acquisition of 33,150 stock options granted to managing director Michael Lee for his board service.

Shattuck Labs Director Clay B. Siegall acquired 33,150 stock options with an exercise price of $0.82, vesting over one year or prior to the next annual meeting.

Shattuck Labs, Inc. director Amy Kate Sasser was granted options to purchase 33,150 shares of common stock with an exercise price of $0.82, vesting over one year.

Shattuck Labs, Inc. Director George Golumbeski has acquired 33,150 stock options with an exercise price of $0.82, vesting on the earlier of one year or the next annual meeting.

Shattuck Labs, Inc. Director Neil W. Gibson was granted options to purchase 33,150 shares of common stock at an exercise price of $0.82 per share, vesting based on continued service.

Shattuck Labs, Inc. Director Carrie Brownstein was granted 33,150 stock options with an exercise price of $0.82 per share, vesting over one year or prior to the next annual meeting.

Shattuck Labs, Inc. Director Tyler Brous was granted 33,150 stock options with an exercise price of $0.82, vesting on the earlier of one year or the next annual meeting.

Shattuck Labs, Inc. Director Helen M. Boudreau was granted 33,150 stock options with an exercise price of $0.82, vesting on the earlier of one year from the grant date or the next annual meeting.

Abhinav A. Shukla, Chief Technical Officer of Shattuck Labs, reports the acquisition of stock options and the disposal of shares to cover tax obligations.

Casi DeYoung, Chief Business Officer of Shattuck Labs, reports the acquisition of stock options and the disposal of shares to cover tax obligations.

Shattuck Labs' Chief Medical Officer, Arundathy N. Pandite, reported the disposition of 3,211 shares and the acquisition of 206,200 stock options.

Stephen Stout, General Counsel at Shattuck Labs, was granted stock options for 177,000 shares of common stock.

Andrew R. Neill, CFO of Shattuck Labs, Inc., was granted options to purchase 214,000 shares of the company's common stock on January 28, 2025.

Shattuck Labs CEO, Taylor Schreiber, was granted stock options for 684,600 shares, vesting over a four-year period.

Arundathy N. Pandite, Chief Medical Officer of Shattuck Labs, sold 6,884 shares of common stock to cover tax obligations.

Casi DeYoung, Chief Business Officer of Shattuck Labs, reports disposing of 5,727 shares of common stock to cover tax obligations.

Abhinav A. Shukla, Chief Technical Officer of Shattuck Labs, Inc., reported disposing of 4,830 shares of common stock on January 10, 2025.